+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region



Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region



Papillomavirus Research 2: 61-69



We estimated the proportion of cervical intraepithelial neoplasia (CIN) cases attributed to 14 HPV types, including quadrivalent (qHPV) (6/11/16/18) and 9-valent (9vHPV) (6/11/16/18/31/33/45/52/58) vaccine types, by region METHODS: Women ages 15-26 and 24-45 years from 5 regions were enrolled in qHPV vaccine clinical trials. Among 10,706 women (placebo arms), 1539 CIN1, 945 CIN2/3, and 24 adenocarcinoma in situ (AIS) cases were diagnosed by pathology panel consensus. Predominant HPV types were 16/51/52/56 (anogenital infection), 16/39/51/52/56 (CIN1), and 16/31/52/58 (CIN2/3). In regions with largest sample sizes, minimal regional variation was observed in 9vHPV type prevalence in CIN1 (~50%) and CIN2/3 (81-85%). Types 31/33/45/52/58 accounted for 25-30% of CIN1 in Latin America and Europe, but 14-18% in North America and Asia. Types 31/33/45/52/58 accounted for 33-38% of CIN2/3 in Latin America (younger women), Europe, and Asia, but 17-18% of CIN2/3 in Latin America (older women) and North America. Non-vaccine HPV types 35/39/51/56/59 had similar or higher prevalence than qHPV types in CIN1 and were attributed to 2-11% of CIN2/3. The 9vHPV vaccine could potentially prevent the majority of CIN1-3, irrespective of geographic region. Notwithstanding, non-vaccine types 35/39/51/56/59 may still be responsible for some CIN1, and to a lesser extent CIN2/3.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059814571

Download citation: RISBibTeXText

PMID: 29074187

DOI: 10.1016/j.pvr.2016.03.002


Related references

Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia. International Journal of Cancer 120(1): 55-59, 2006

Comparative proteome analysis of human papillomavirus-infected cervical specimens and the difference between the high- and low-risk genotypes of human papillomavirus. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae 29(5): 597-602, 2007

Comparison of the AdvanSure human papillomavirus screening real-time PCR, the Abbott RealTime High Risk human papillomavirus test, and the Hybrid Capture human papillomavirus DNA test for the detection of human papillomavirus. Annals of Laboratory Medicine 32(3): 201-205, 2012

Distribution of high-risk human papillomavirus genotypes among HIV-negative women with and without cervical intraepithelial neoplasia in South Africa. Plos One 7(9): E44332, 2013

Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. Journal of Clinical Microbiology 45(2): 364-369, 2006

High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer. International Journal of Cancer 124(2): 381-386, 2009

Phylogenetic classification of human papillomavirus genotypes in high-grade cervical intraepithelial neoplasia in women from a densely populated Brazilian urban region. Sao Paulo Medical Journal 127(3): 122-127, 2010

Phylogenetic classification of human papillomavirus genotypes in high-grade cervical intraepithelial neoplasia in women from a densely populated Brazilian urban region. Sao Paulo Medical Journal 127(3): 122-127, 2009

PCR detection rates of high risk human papillomavirus DNA in paired self-collected urine and cervical scrapes after laser CO2 conization for high-grade cervical intraepithelial neoplasia. Gynecologic Oncology 109(1): 59-64, 2008

Detection of high-risk human papillomavirus subtypes in cervical glandular neoplasia by in situ hybridization. International Journal of Clinical and Experimental Pathology 6(10): 2168-2177, 2014

Detection of high-risk human papillomavirus (HPV) E6 and E7 oncogene transcripts increases the specificity of the detection of a cervical intraepithelial neoplasia (CIN). Verhandlungen der Deutschen Gesellschaft für Pathologie 89: 195-200, 2007

Distribution and role of high-risk human papillomavirus genotypes in women with cervical intraepithelial neoplasia: A retrospective analysis from Wenzhou, southeast China. Cancer Medicine 2018, 2018

Comparison of Human Papillomavirus DNA Testing and Cervical Spectroscopy Combined With Cervical Cytology for the Detection of High-grade Neoplasia in a Population of High-risk Women Referred for Colposcopy. Journal of Lower Genital Tract Disease 10(3): 175-176, 2006

Associations of human leukocyte antigen class II genotypes with human papillomavirus 18 infection and cervical intraepithelial neoplasia risk. Cancer 118(1): 223-231, 2012

Unique variants of human papillomavirus genotypes 52 and 58 and risk of cervical neoplasia. International Journal of Cancer 129(4): 965-973, 2011